EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Prognostic value of systemic immune-inflammation index/albumin ratio for immunotherapy-treated patients receiving opioids

Lei Yan, Pan Kang, Chengsong Cao, Bu Jinhui, Liu Yong iD

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0305119 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Lei Yan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Xuzhou Clinical School of Xuzhou Medical University, Xuzhou, Jiangsu, China. Hauptthemen laut MEDLINE: Analgesics, Opioid, Immunotherapy, Inflammation, Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This study evaluated the effect of the systemic immune-inflammation index/albumin ratio (SII/ALB) on the prognosis of immunotherapy-treated patients receiving opioids.

Methods

A retrospective analysis was conducted of 185 immunotherapy-treated patients who received opioids at Xuzhou Central Hospital from 01/09/2021 to 01/09/2023. The results of related clinical data were collected during the week before the cancer patients received immunotherapy. The SII/ALB cut-off value was determined, and the relationship between the SII/ALB and clinical pathological parameters was analyzed using the chi-square test. The effect of the SII/ALB on progression-free survival (PFS) was examined using Kaplan-Meier curves and the Cox proportional hazard model.

Result

The SII/ALB cut-off value was 20.86, and patients were divided into low (SII/ALB ≤ 20.86) and high (SII/ALB > 20.86) SII/ALB groups. Adverse reactions (hazard ratio [HR] = 0.108; 95% confidence interval [CI]: 0.061–0.192, P < 0.001) and the SII/ALB (HR = 0.093; 95% CI: 0.057–0.151, P < 0.001) were independent prognostic factors for PFS. Compared with the high SII/ALB group, the low SII/ALB group had longer PFS after opioid treatment (12.2 vs. 5.2 months, P < 0.001).

Conclusion

The SII/ALB is a potentially important prognostic parameter in immunotherapy-treated patients receiving opioids.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Analgesics, OpioidImmunotherapyInflammationNeoplasmsHumansFemaleMaleMiddle AgedPrognosisRetrospective StudiesAgedAdultKaplan-Meier EstimateSerum AlbuminProportional Hazards ModelsAged, 80 and over

Substanzen

Analgesics, OpioidSerum Albumin

Autor:innen und Institutionen

  • Xuzhou Clinical School of Xuzhou Medical University, Xuzhou, Jiangsu, China.
  • Department of Oncology, Xuzhou Central Hospital, Xuzhou Clinical School of Xuzhou Medical University, Xuzhou Central Hospital Affiliated to Nanjing University of Chinese Medicine, The Xuzhou School of Clinical Medicine…

ORCID-Profile: Liu Yong

Zitieren

APA

Yan, L., Kang, P., Cao, C., Jinhui, B., & Yong, L. (2024). Prognostic value of systemic immune-inflammation index/albumin ratio for immunotherapy-treated patients receiving opioids. PLOS ONE. https://doi.org/10.1371/journal.pone.0305119

Vancouver

Yan L, Kang P, Cao C, Jinhui B, Yong L. Prognostic value of systemic immune-inflammation index/albumin ratio for immunotherapy-treated patients receiving opioids. PLOS ONE. 2024. doi:10.1371/journal.pone.0305119

BibTeX
@article{Yan2024,
  author = {Yan, Lei and Kang, Pan and Cao, Chengsong and Jinhui, Bu and Yong, Liu},
  title = {Prognostic value of systemic immune-inflammation index/albumin ratio for immunotherapy-treated patients receiving opioids},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0305119}
}
Kostenlos starten →